期刊
MOLECULAR CANCER RESEARCH
卷 9, 期 8, 页码 997-1007出版社
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1541-7786.MCR-10-0490
关键词
-
资金
- NIGMS [R01 GM63090]
- National Cancer Institute [R01 CA127727]
- Robert B. Goergen Prostate Cancer Foundation
- Duke Cancer Institute [5K12-CA-100639-05]
- Department of Defense [W81XWH-10-1-0483]
- American Cancer Society
- H.L. Kirkpatrick Foundation
- National Research Service [T32-CA059365, F32 CA142095]
During cancer progression, malignant cells undergo epithelial-mesenchymal transitions (EMT) and mesenchymal-epithelial transitions (MET) as part of a broad invasion and metastasis program. We previously observed MET events among lung metastases in a preclinical model of prostate adenocarcinoma that suggested a relationship between epithelial plasticity and metastatic spread. We thus sought to translate these findings into clinical evidence by examining the existence of EMT in circulating tumor cells (CTC) from patients with progressive metastatic solid tumors, with a focus on men with castration-resistant prostate cancer (CRPC) and women with metastatic breast cancer. We showed that the majority (>80%) of these CTCs in patients with metastatic CRPC coexpress epithelial proteins such as epithelial cell adhesion molecule (EpCAM), cytokeratins (CK), and E-cadherin, with mesenchymal proteins including vimentin, N-cadherin and O-cadherin, and the stem cell marker CD133. Equally, we found that more than 75% of CTCs from women with metastatic breast cancer coexpress CK, vimentin, and N-cadherin. The existence and high frequency of these CTCs coexpressing epithelial, mesenchymal, and stem cell markers in patients with progressive metastases has important implications for the application and interpretation of approved methods to detect CTCs. Mol Cancer Res; 9(8); 997-1007. (C)2011 AACR.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据